Advanced search
Publication Cover
Expert Review of Clinical Immunology Volume 7, 2011 - Issue 5
Submit an article Journal homepage
138
Views
10
CrossRef citations to date
0
Altmetric
Drug Profile

Cinryze™ (C1-inhibitor) for the treatment of hereditary angioedema

Mark M Gompels Immunology and Immunogenetics, Pathology Sciences, North Bristol NHS Trust, Southmead Hospital, Bristol, BS10 5NB, UK;[email protected]
&
Robert John Lock Immunology and Immunogenetics, Pathology Sciences, North Bristol NHS Trust, Southmead Hospital, Bristol, BS10 5NB, UK; Immunology and Immunogenetics, Pathology Sciences, North Bristol NHS Trust, Southmead Hospital, Bristol, BS10 5NB, UK
Pages 569-573 | Published online: 10 Jan 2014

References

  • Frank MM. 8. Hereditary angioedema. J. Allergy Clin. Immunol.121(Suppl. 2), S398–S401; quiz S419 (2008).
  • Blanch A, Roche O, Urrutia I, Gamboa P, Fontán G, López-Trascasa M. First case of homozygous C1 inhibitor deficiency. J. Allergy Clin. Immunol.118, 1330–1335 (2006). Erratum in: J. Allergy Clin. Immunol.119, 745 (2007).
  • López-Lera A, Favier B, de la Cruz RM, Garrido S, Drouet C, López-Trascasa M. A new case of homozygous C1-inhibitor deficiency suggests a role for Arg378 in the control of kinin pathway activation. J. Allergy Clin. Immunol.126, 1307–1310 e3 (2010).
  • Prada AE, Zahedi K, Davis AE. Regulation of C1-inhibitor synthesis. Immunobiology199, 377–788 (1998).
  • Bork K, Barnstedt S, Koch P, Traupe H. Hereditary angioedema with normal C1-inhibitor activity in women. Lancet356, 213–217 (2000).
  • Vitrat-Hincky V, Gompel A, Dumestre-Perard C et al. Type III hereditary angio-oedema: clinical and biological features in a French cohort. Allergy65, 1331–1336 (2010).
  • Bas M, Adams V, Suvorava T, Niehues T, Hoffmann TK, Kojada G. Nonallergic angioedema: role of bradykinin. Allergy62, 842–856 (2010).
  • Kaplan AP. Enzymatic pathways in the pathogenesis of hereditary angioedema: The role of C1 inhibitor therapy. J. Allergy Clin. Immunol.126, 918–925 (2010).
  • Krassilnikova S, Craig ET, Craig TJ. Summary of the International Multicenter Prospective Angioedema C1-inhibitor Trials 1 and 2 (IMPACT1 and 2). Expert Rev. Clin. Immunol.6, 327–334 (2010).
  • Farkas H, Gyeney L, Gidofalvy E, Fust G, Varga L. The efficacy of short-term danazol prophylaxis in hereditary angioedema patients undergoing maxillofacial and dental procedures. J. Oral Maxillofac. Surg.57, 404–408 (1999).
  • Gompels MM, Lock RJ, Abinun M et al. C1 inhibitor deficiency: consensus document. Clin. Exp. Immunol.139, 379–394 (2005).
  • Bowen T, Cicardi M, Bork K et al. Hereditary angiodema: a current state-of-the-art review, VII: Canadian Hungarian 2007 International consensus algorithm for the diagnosis, therapy, and management of hereditary angioedema. Ann. Allergy Asthma Immunol.100(Suppl. 2), S30–S40 (2008).
  • Bowen T, Cicardi M, Farkas H et al. International consensus algorithm for the diagnosis, therapy and management of hereditary angioedema. Allergy Asthma Clin. Immunol.6, 24 (2010).
  • Bork K. Pasteurized C1 inhibitor concentrate in hereditary angioedema: pharmacology, safety, efficacy and future directions. Expert Rev. Clin. Immunol.4, 13–20 (2008).
  • Zuraw BL, Busse PJ, White M et al. Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedema. N. Engl. J. Med.363, 513–522 (2010).
  • van Doorn MB, Burggraaf J, van Dam T et al. A phase I study of recombinant human C1 inhibitor in asymptomatic patients with hereditary angioedema J. Allergy Clin. Immunol.116, 876–883 (2005).
  • Frank MM, Gelfand JA, Atkinson JP. Hereditary angioedema: the clinical syndrome and its management. Ann. Intern. Med.84, 580–593 (1976).
  • Longhurst HJ, Farkas H, Craig T et al. HAE international home therapy consensus document. Allergy Asthma Clin. Immunol.6, 22 (2010).
  • Zuraw B, Cicardi M, Levy RJ et al. Recombinant human C1-inhibitor for the treatment of acute angioedema attacks in patients with hereditary angioedema. J. Allergy Clin. Immunol.126, 821–827 (2010).
  • Cicardi M, Banerji A, Bracho F et al. Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema. N. Engl. J. Med.363, 532–541 (2010).
  • Cicardi M, Levy RJ, McNeil DL et al. Ecallantide for the treatment of acute attacks in hereditary angioedema. N. Engl. J. Med.363, 523–531 (2010).
  • Caliezi C, Zeerleder S, Redondo M et al. C1-inhibitor in patients with severe sepsis and septic shock: beneficial effect on renal dysfunction. Crit. Care Med.30, 1722–1728 (2002).
  • Caliezi C, Wuillemin WA, Zeerleder S, Redondo M, Eisele B, Hack CE. C1-esterase inhibitor: An anti-inflammatory agent and its potential use in the treatment of diseases other than hereditary angioedema. Pharmacol. Rev.52, 91–112 (2000).
  • Bork K, Bygum A, Hardt J. Benefits and risks of danazol in hereditary angioedema: a long-term survey of 118 patients. Ann. Allergy Asthma Immunol.100, 153–161 (2008).

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.